Sepracor hires execs from Novartis, GSK

Share this article:

Sepracor hired four former Novartis and GlaxoSmithKline marketing and sales executives as it firmed up its senior commercial management staff.

The Massachusetts company, whose biggest product is the sleep drug Lunesta, appointed Mark Iwicki EVP and chief commercial officer, a new position. Iwicki joined from Novartis, where he led the cardiovascular business franchise.

Also from Novartis, Sepracor brought in Jay Smith as SVP of sales. At Novartis Smith served as national VP of sales and head of cardiovascular innovations marketing.

The two former GSK executives included Dean Giovanniello, whom Sepracor hired as VP of marketing, and Thomas Hoover, named VP of new products planning. Giovanniello was most recently executive director of marketing for GSK's migraine products, while Hoover served as its therapy area head, business and commercial analysis.

Sepracor said the new hires were part of an effort “to deliver enhanced performance and productivity across our commercial organization.”

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...